SANTA BARBARA, Calif.--(BUSINESS WIRE)--Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, announced today that subject enrollment and initial dosing in its pivotal Phase IIIb study of its investigational botulinum toxin type A for the reduction of glabellar rhytides (frown lines) by intramuscular injection has been completed. Enrollment in the IIIb trial, which consisted of 700 subjects, began in late November and was completed in mid January.
